Physiopathology, Diagnosis, and Treatment of Hyperprolactinemia

Reference work entry
Part of the Endocrinology book series (ENDOCR)

Abstract

Prolactin is a pituitary hormone that plays a pivotal role in a variety of reproductive functions. Hyperprolactinemia is a common condition that can result from a number of causes, including medication use and hypothyroidism as well as pituitary disorders. Depending on the cause and consequences of the hyperprolactinemia, selected patients require treatment. The underlying cause, sex, age, and reproductive status must be considered.

Keywords

Prolactin Hyperprolactinemia Treatment Dopamine agonist Pregnancy Resistance Cure 

References

  1. Ahmed M, Banna M, Sakati N, Woodhouse N. Pituitary gland enlargement in primary hypothyroidism: a report of 5 cases with follow-up data. Horm Res. 1989;32:188–92.PubMedCrossRefGoogle Scholar
  2. Amar AP, Couldwell WT, Chen JC, Weiss MH. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J Neurosurg. 2002;97:307–14.PubMedCrossRefGoogle Scholar
  3. Amit T, Dibner C, Barkey RJ. Characterization of prolactin and growth hormone-binding proteins in milk and their diversity among species. Mol Cell Endocrinol. 1997;130:167–80.PubMedCrossRefGoogle Scholar
  4. Anagnostis P, Adamidou F, Polyzos SA, Efstathiadou Z, Karathanassi E, Kita M. Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary. 2012;15:25–9.PubMedCrossRefGoogle Scholar
  5. Arafah BM, Nekl KE, Gold RS, Selman WR. Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas. J Clin Endocrinol Metab. 1995;80:3507–12.PubMedGoogle Scholar
  6. Arslan MS, Topaloglu O, Sahin M, Tutal E, Gungunes A, Cakir E, Ozturk IU, Karbek B, Ucan B, Ginis Z, Cakal E, Ozbek M, Delibasi T. Preclinical atherosclerosis in patients with prolactinoma. Endocr Pract. 2014;20:447–51.PubMedCrossRefGoogle Scholar
  7. Arunakaran J, Balasubramanian K, Srinivasan N, Aruldhas MM, Govindarajulu P. Effects of androgens, prolactin and bromocriptine on seminal vesicular enzymes of the pyruvate malate cycle involved in lipogenesis in castrated mature monkeys, macaca radiata. Int J Androl. 1988;11:133–9.PubMedCrossRefGoogle Scholar
  8. Atasoy M, Karatay S, Yildirim K, Kadi M, Erdem T, Senel K. The relationship between serum prolactin levels and disease activity in patients with Behcet’s disease. Cell Biochem Funct. 2006;24:353–6.PubMedCrossRefGoogle Scholar
  9. Babey M, Sahli R, Vajtai I, Andres RH, Seiler RW. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary. 2011;14:222–30.PubMedCrossRefGoogle Scholar
  10. Balbach L, Wallaschofski H, Völzke H, Nauck M, Dörr M, Haring R. Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes? BMC Endocr Disord. 2013;13:12–9.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Barber TM, Kenkre J, Garnett C, Scott RV, Byrne JV, Wass JA. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma. Clin Endocrinol. 2011;75:819–24.CrossRefGoogle Scholar
  12. Bart G, Borg L, Schluger JH, Green M, Ho A, Kreek MJ. Suppressed prolactin response to dynorphin A1-13 in methadone-maintained versus control subjects. J Pharmacol Exp Ther. 2003;306:581–7.PubMedCrossRefGoogle Scholar
  13. Beer TM, Bland LB, Bussiere JR, Neiss MB, Wersinger EM, Garzotto M, Ryan CW, Janowsky JS. Testosterone loss and estradiol administration modify memory in men. J Urol. 2006;175:130–5.PubMedCrossRefGoogle Scholar
  14. Behan LA, Draman MS, Moran C, King T, Crowley RK, O'Sullivan EP, Smith D, Thompson CJ, Agha A. Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review. Pituitary. 2011;14:362–6.PubMedCrossRefGoogle Scholar
  15. Bellantuono C, Santone G. Efficacy, tolerability and safety of paliperidone extended-release in the treatment of schizophrenia and schizoaffective disorder. Riv Psichiatr. 2012;47:5–20.PubMedGoogle Scholar
  16. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev. 1996;17:639–69.PubMedGoogle Scholar
  17. Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab. 2006;17:110–6.PubMedCrossRefGoogle Scholar
  18. Berchtold S, Volarevic S, Moriggl R, Mercep M, Groner B. Dominant negative variants of the SHP-2 tyrosine phosphatase inhibit prolactin activation of Jak2 (janus kinase 2) and induction of Stat5 (signal transducer and activator of transcription 5)-dependent transcription. Mol Endocrinol. 1998;12:556–67.PubMedCrossRefGoogle Scholar
  19. Berinder K, Akre O, Granath F, Hulting AL. Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur J Endocrinol. 2011;165:209–15.PubMedCrossRefGoogle Scholar
  20. Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C. Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance. Encéphale. 2014;40:86–94.PubMedCrossRefGoogle Scholar
  21. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM, Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536–59.PubMedCrossRefGoogle Scholar
  22. Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol. 2005;63:26–31.CrossRefGoogle Scholar
  23. Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, Boresi F, Taddei S, Salvetti A, Martino E. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract. 2008;62:1864–9.PubMedCrossRefGoogle Scholar
  24. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev. 1998;19:225–68.PubMedCrossRefGoogle Scholar
  25. Bonert VS, Melmed S (2006) Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. Nat Clin Pract Endocrinol Metab 2: 408-12Google Scholar
  26. Brandebourg T, Hugo E, Ben-Jonathan N. Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab. 2007;9:464–76.PubMedCrossRefGoogle Scholar
  27. Brelje TC, Stout LE, Bhagroo NV, Sorenson RL. Distinctive roles for prolactin and growth hormone in the activation of signal transducer and activator of transcription 5 in pancreatic islets of langerhans. Endocrinology. 2004;145:4162–75.PubMedCrossRefGoogle Scholar
  28. Brown RS, Herbison AE, Grattan DR. Prolactin regulation of kisspeptin neurones in the mouse brain and its role in the lactation-induced suppression of kisspeptin expression. J Neuroendocrinol. 2014;26:898–908.PubMedCrossRefGoogle Scholar
  29. Buchfelder M, Schlaffer S. Surgical treatment of pituitary tumours. Best Pract Res Clin Endocrinol Metab. 2009;23:677–92.PubMedCrossRefGoogle Scholar
  30. Buvat J, Shabsigh R, Guay A, Gooren L, Torres LO, Meuleman E. Hormones, metabolism, aging, and men’s health. In: Montorsi F, Basson R, Adaikan G, Becher E, Clayton A, Giuliano F, et al., editors. Standard practice in sexual medicine. Oxford: Blackwell Publishing; 2006. p. 225–86.CrossRefGoogle Scholar
  31. Byerly M, Suppes T, Tran QV, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol. 2007;27:639–61.PubMedCrossRefGoogle Scholar
  32. Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, Jaquet P, Kordon C, Enjalbert A. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology. 1994;60:314–22.PubMedCrossRefGoogle Scholar
  33. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Law E, Marek J, Scanlon M, Sobrinho LG, Wass JAH. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006;65:265–73.CrossRefGoogle Scholar
  34. Castinetti F, Nagai M, Morange I, Dufour H, Caron P, Chanson P, Cortet-Rudelli C, Kuhn JM, Conte-Devolx B, Regis J, Brue T. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab. 2009;94:3400–7.PubMedCrossRefGoogle Scholar
  35. Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry. 2004;65:187–90.PubMedCrossRefGoogle Scholar
  36. Chandrashekar V, Bartke A. Influence of endogenous prolactin on the luteinizing hormone stimulation of testicular steroidogenesis and the role of prolactin in adult male rats. Steroids. 1988;51:559–76.PubMedCrossRefGoogle Scholar
  37. Chavez-Rueda K, Hernandez J, Zenteno E, Leanos-Miranda A, Legorreta-Haquet MV, Blanco-Favela F. Identification of prolactin as a novel immunomodulator on the expression of co-stimulatory molecules and cytokine secretions on T and B human lymphocytes. Clin Immunol. 2005;116:182–91.PubMedCrossRefGoogle Scholar
  38. Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs. 2010;70:1295–317.PubMedCrossRefGoogle Scholar
  39. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev. 2003;24:1–27.PubMedPubMedCentralCrossRefGoogle Scholar
  40. Cohen LG, Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol. 2001;11:435–40.PubMedCrossRefGoogle Scholar
  41. Cohen-Inbar O, Xu Z, Schlesinger D, Vance ML, Sheehan JP. Gamma knife radiosurgery for medically and surgically refractory prolactinomas: long-term results. Pituitary. 2015;18:820–30.PubMedCrossRefGoogle Scholar
  42. Colao A. Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab. 2009;23:575–96.PubMedCrossRefGoogle Scholar
  43. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 1997;82:876–83.PubMedCrossRefGoogle Scholar
  44. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med. 2003;349:2023–33.PubMedCrossRefGoogle Scholar
  45. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab. 2008;93:3777–84.PubMedCrossRefGoogle Scholar
  46. Cookson J. Oestrogens, dopamine and mood. Br J Psychiatry. 1981;139:365–6.PubMedCrossRefGoogle Scholar
  47. Corona G, Mannucci E, Fisher AD, Lotti F, Ricca V, Balercia G, Petrone L, Forti G, Maggi M. Effect of hyperprolactinemia in male patients consulting for sexual dysfunction. J Sex Med. 2007;4:1485–93.PubMedCrossRefGoogle Scholar
  48. Cosman D, Lyman SD, Idzerda RL, Beckmann MP, Park LS, Goodwin RG, March CJ. A new cytokine receptor superfamily. Trends Biochem Sci. 1990;15:265–70.PubMedCrossRefGoogle Scholar
  49. Couldwell WT, Weiss MH. Medical and surgical management of microprolactinoma. Pituitary. 2004;7:31–2.PubMedCrossRefGoogle Scholar
  50. Craig MC, Fletcher PC, Daly EM, Rymer J, Cutter WJ, Brammer M, Giampietro V, Wickham H, Maki PM, Murphy DG. Gonadotropin hormone releasing hormone agonists alter prefrontal function during verbal encoding in young women. Psychoneuroendocrinology. 2007;32:1116–27.PubMedCrossRefGoogle Scholar
  51. Craig MC, Fletcher PC, Daly EM, Picchioni MM, Brammer M, Giampietro V, Rymer J, McGuire PK, Maki PM, Murphy DG. A study of visuospatial working memory pre- and post-Gonadotropin Hormone Releasing Hormone agonists (GnRHa) in young women. Horm Behav. 2008;54:47–59.PubMedCrossRefGoogle Scholar
  52. Crambert S, Sjoberg A, Eklof AC, Ibarra F, Holtback U. Prolactin and dopamine 1-like receptor interaction in renal proximal tubular cells. Am J Phys. 2010;299:F49–54.Google Scholar
  53. Creemers LB, Zelissen PM, van’t Verlaat JW, Koppeschaar HP. Prolactinoma and body weight: a retrospective study. Acta Endocrinol. 1991;125:392–6.PubMedGoogle Scholar
  54. Cruz N, Vieta E. Asenapine: a new focus on the treatment of mania. Rev Psiquiatr Salud Ment. 2011;4:101–8.PubMedCrossRefGoogle Scholar
  55. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91:4769–75.PubMedCrossRefGoogle Scholar
  56. Das R, Vonderhaar BK. Prolactin as a mitogen in mammary cells. J Mammary Gland Biol Neoplasia. 1997;2:29–39.PubMedCrossRefGoogle Scholar
  57. De Bellis A, Bizzarro A, Pivonello R, Lombardi G, Bellastella A. Prolactin and autoimmunity. Pituitary. 2005;8:25–30.PubMedCrossRefGoogle Scholar
  58. Dekkers OM, Lagro J, BurmanP JJO, Romijn JA, Pereira AM. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab. 2010a;95:43–51.PubMedCrossRefGoogle Scholar
  59. Dekkers OM, Romijn JA, de Boer A, Vandenbroucke JP. The risk for breast cancer is not evidently increased in women with hyperprolactinemia. Pituitary. 2010b;13:195–8.PubMedCrossRefGoogle Scholar
  60. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab. 1997;82:2102–7.PubMedGoogle Scholar
  61. Delgrange E, Donckier J, Maiter D. Hyperprolactinaemia as a reversible cause of weight gain in male patients? Clin Endocrinol. 1999;50:271.CrossRefGoogle Scholar
  62. Delgrange E, Daems T, Verhelst J, Abs R, Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol. 2009;160:747–52.PubMedCrossRefGoogle Scholar
  63. Demura R, Ono M, Demura H, Shizume K, Oouchi H. Prolactin directly inhibits basal as well as gonadotropin-stimulated secretion of progesterone and 17b-estradiol in the human ovary. J Clin Endocrinol Metab. 1982;54:1246–50.PubMedCrossRefGoogle Scholar
  64. Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol. 2002;147:77–84.PubMedCrossRefGoogle Scholar
  65. Dombrowicz D, Sente B, Closset J, Hennen G. Dose-dependent effects of human prolactin on the immature hypophysectomized rat testis. Endocrinology. 1992;130:695–700.PubMedGoogle Scholar
  66. Dorrington JH, Gore-Langton RE. Antigonadal action of prolactin: further studies on the mechanism of inhibition of follicle-stimulating hormone-induced aromatase activity in rat granulosa cell cultures. Endocrinology. 1982;110:1701–7.PubMedCrossRefGoogle Scholar
  67. Drago F, Pellegrini-Quarantotti B, Scapagnini U, Gessa GL. Short-term endogenous hyperprolactinemia and sexual behaviour of me rats. Physiol Behav. 1981;26:277–9.PubMedCrossRefGoogle Scholar
  68. Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma. Clin Endocrinol. 2010;73:502–27.Google Scholar
  69. Ernst B, Thurnheer M, Schultes B. Basal serum prolactin levels in obesity-unrelated to parameters of the metabolic syndrome and unchanged after massive weight loss. Obes Surg. 2009;19:1159–62.PubMedCrossRefGoogle Scholar
  70. Faupel-Badger JM, Duggan MA, Sherman ME, Garcia-Closas M, Yang XR, Lissowska J, Brinton LA, Peplonska B, Vonderhaar BK, Figueroa JD. Prolactin receptor expression and breast cancer: relationships with tumor characteristics among pre- and post-menopausal women in a population-based case-control study from Poland. Horm Cancer. 2014;5:42–50.PubMedCrossRefGoogle Scholar
  71. Fava M, Fava GA, Kellner R, Buckman MT, Lisansky J, Serafini E, DeBesi L, Mastrogiacomo I. Psychosomatic aspects of hyperprolactinemia. Psychother Psychosom. 1983;40:257–62.PubMedCrossRefGoogle Scholar
  72. Feldman M, Ruan W, Cunningham BC, Wells JA, Kleinberg DL. Evidence that the growth hormone receptor mediates differentiation and development of the mammary gland. Endocrinology. 1993;133:1602–8.PubMedCrossRefGoogle Scholar
  73. Feltus FA, Groner B, Melner MH. Stat5-mediated regulation of the human type II 3b-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene: activation by prolactin. Mol Endocrinol. 1999;13:1084–93.PubMedGoogle Scholar
  74. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol. 2010;72:377–82.CrossRefGoogle Scholar
  75. Frantz AG. Prolactin. N Engl J Med. 1978;298:201–7.PubMedCrossRefGoogle Scholar
  76. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function and regulation of secretion. Physiol Rev. 2000;80:1523–631.PubMedCrossRefGoogle Scholar
  77. Freemark M, Avril I, Fleenor D, Driscoll P, Petro A, Opara E, Kendall W, Oden J, Bridges S, Binart N, Breant B, Kelly PA. Targeted deletion of the PRL receptor: effects on islet development, insulin production, and glucose tolerance. Endocrinology. 2002;143:1378–85.PubMedCrossRefGoogle Scholar
  78. Friedrich N, Schneider HJ, Spielhagen C, Markus MR, Haring R, Grabe HJ, Buchfelder M, Wallaschofski H, Nauck M. The association of serum prolactin concentration with inflammatory biomarkers – cross-sectional findings from the population-based Study of Health in Pomerania. Clin Endocrinol. 2011;75:561–6.CrossRefGoogle Scholar
  79. Fuh G, Wells JA. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J Biol Chem. 1995;270:13133–7.PubMedCrossRefGoogle Scholar
  80. Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I, Lykka M, Kyrkou K, Rizos D, Creatsa M, Christodoulakos G, Alevizaki M, Sfikakis PP, Papamichael C. Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension. 2009;54:98–105.PubMedCrossRefGoogle Scholar
  81. Gettler LT, McDade TW, Feranil AB, Kuzawa CW. Prolactin, fatherhood, and reproductive behavior in human males. Am J Phys Anthropol. 2012;148:362–70.PubMedCrossRefGoogle Scholar
  82. Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab. 2005;90:3927–32.PubMedCrossRefGoogle Scholar
  83. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27:485–534.PubMedCrossRefGoogle Scholar
  84. Glass MR, Shaw RW, Butt WR, Edwards RL, London DR. An abnormality of oestrogen feedback in amenorrhoea–galactorrhoea. Br Med J. 1975;3:274–5.PubMedPubMedCentralCrossRefGoogle Scholar
  85. Goffin V, Kelly PA. The prolactin/growth hormone receptor family: structure/function relationships. J Mammary Gland Biol Neoplasia. 1997;2:7–17.PubMedCrossRefGoogle Scholar
  86. Goffin V, Shiverick KT, Kelly PA, Martial JA. Sequence function relationships within the expanding family of prolactin, growth hormone, placental lactogen and related proteins in mammals. Endocr Rev. 1996;17:385–410.PubMedGoogle Scholar
  87. Goffin V, Bernichtein S, Touraine P, Kelly P. Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev. 2005;26:400–22.PubMedCrossRefGoogle Scholar
  88. Goldhar AS, Vonderhaar BK, Trott JF, Hovey RC. Prolactin induced expression of vascular endothelial growth factor via Egr-1. Mol Cell Endocrinol. 2005;232:9–19.PubMedCrossRefGoogle Scholar
  89. Green AI, Brown WA. Prolactin and neuroleptic drugs. Endocrinol Metab Clin N Am. 1988;17:213–23.Google Scholar
  90. Greenspan SL, Neer RM, Ridgway EC, Klibanski A. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med. 1986;104:777–82.PubMedCrossRefGoogle Scholar
  91. Greenspan SL, Oppenheim DS, Klibanski A. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med. 1989;110:526–31.PubMedCrossRefGoogle Scholar
  92. Grigorova M, Sherwin BB, Tulandi T. Effects of treatment with leuprolide acetate depot on working memory and executive functions in young premenopausal women. Psychoneuroendocrinology. 2006;31:935–47.PubMedCrossRefGoogle Scholar
  93. Gunasekar PG, Kumaran B, Govindarajulu P. Prolactin and leydig cell steroidogenic enzymes in the bonnet monkey (macaca radiata). Int J Androl. 1988;11:53–9.PubMedCrossRefGoogle Scholar
  94. Gunasekar PG, Kumaran B, Govindarajulu P. Role of prolactin on leydig, sertoli and germ cellular neutral lipids in bonnet monkeys, macaca radiata. Endocrinologia Japonica. 1991;38:1–8.PubMedCrossRefGoogle Scholar
  95. Hair WM, Gubbay O, Jabbour HN, Lincoln GA. Prolactin receptor expression in human testis and accessory tissues: localization and function. Mol Hum Reprod. 2002;8:606–11.PubMedCrossRefGoogle Scholar
  96. Hamosh M, Hamosh P. The effect of prolactin on the lecithin content of fetal rabbit lung. J Clin Invest. 1977;59:1002–5.PubMedPubMedCentralCrossRefGoogle Scholar
  97. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B, Speizer FE. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1999;91:629–34.PubMedCrossRefGoogle Scholar
  98. Harvey PW, Everett DJ, Springall CJ. Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer. Hum Exp Toxicol. 2006;25:395–404.PubMedCrossRefGoogle Scholar
  99. Harvey PW, Everett DJ, Springall CJ. Adverse effects of prolactin in rodents and humans: breast and prostate cancer. J Psychopharmacol. 2008;22:20–7.PubMedCrossRefGoogle Scholar
  100. Henry JF, Sherwin BB. Hormones and cognitive functioning during late pregnancy and postpartum: a longitudinal study. Behav Neurosci. 2012;126:73–85.PubMedCrossRefGoogle Scholar
  101. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol. 2009;70:104–8.CrossRefGoogle Scholar
  102. Honbo KS, van Herle AJ, Kellett KA. Serum prolactin levels in untreated primary hypothyroidism. Am J Med. 1978;64:782–7.PubMedCrossRefGoogle Scholar
  103. Horseman ND, Zhao W, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ, Smith F, Markoff E, Dorshkind K. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J. 1997;16:6926–35.PubMedPubMedCentralCrossRefGoogle Scholar
  104. Hou SH, Grossman S, Molitch ME. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis. 1985;6:245–9.PubMedCrossRefGoogle Scholar
  105. Huang KE, Bonfiglio TA, Muechler EK. Transient hyperprolactinemia in infertile women with luteal phase deficiency. Obstet Gynecol. 1991;78:651–5.PubMedGoogle Scholar
  106. Hurel SJ, Harris PE, McNicol AM, Foster S, Kelly WF, Baylis PH. Metastatic prolactinoma: effect of octreotide, cabergoline, carbo-platin and etoposide; immunocytochemical analysis of proto-oncogene expression. J Clin Endocrinol Metab. 1997;82:2962–5.PubMedCrossRefGoogle Scholar
  107. Ibarra F, Crambert S, Eklof AC, Lundquist A, Hansell P, Holtback U. Prolactin, a natriuretic hormone, interacting with renal dopamine system. Kidney Int. 2005;68:1700–7.PubMedCrossRefGoogle Scholar
  108. Ignacak A, Kasztelnik M, Sliwa T, Korbut R, Rajda K, Guzik T. Prolactin not only lactotrophin. A “new” view of the “old” hormone. J Physiol Pharmacol. 2012;63:435–43.PubMedGoogle Scholar
  109. Ikeda H, Watanabe K, Tominaga T, Yoshimoto T. Transsphenoidal microsurgical results of female patients with prolactinomas. Clin Neurol Neurosurg. 2013;115:1621–5.PubMedCrossRefGoogle Scholar
  110. Ishida M, Yoshida M, Fukuta S, Uemura K, Iijima M, Horiguchi K, Harigaya T. Analysis of prolactin gene expression and cleaved prolactin variants in the mouse testis and spermatozoa. J Reprod Dev. 2010;56:567–74.PubMedCrossRefGoogle Scholar
  111. Jabbour HN, Lincoln GA. Prolactin receptor expression in the testis of the ram: localisation, functional activation and the influence of gonadotrophins. Mol Cell Endocrinol. 1999;148:151–61.PubMedCrossRefGoogle Scholar
  112. Janicak PG, Winans EA. Paliperidone ER: a review of the clinical trial data. Neuropsychiatr Dis Treat. 2007;3:869–97.PubMedPubMedCentralCrossRefGoogle Scholar
  113. Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J. Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol. 1996;45:299–303.CrossRefGoogle Scholar
  114. Jezkova J, Hana V, Krsek M, Weiss V, Vladyka V, Liscak R, Vymazal J, Pecen L, Marek J. Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Endocrinol. 2009;70:732–41.CrossRefGoogle Scholar
  115. Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, Turner HE, Wass JA. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol. 2006;65:524–9.CrossRefGoogle Scholar
  116. Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab. 2008;93:3348–56.PubMedCrossRefGoogle Scholar
  117. Kars M, Souverein PC, Herings RM, Romijn JA, Vandenbroucke JP, de Boer A, Dekkers OM. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab. 2009;94:2729–34.PubMedCrossRefGoogle Scholar
  118. Karunakaran S, Page RC, Wass JA. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol. 2001;54:295–300.CrossRefGoogle Scholar
  119. Kato Y, Shimatsu A, Matsushita N, Ohta H, Imura H. Role of vasoactive intestinal polypeptide (VIP) in regulating the pituitary function in man. Peptides. 1984;5:389–94.PubMedCrossRefGoogle Scholar
  120. Kearns AE, Goff DC, Hayden DL, Daniels GH. Risperidone associated hyperprolactinemia. Endocr Pract. 2000;6:425–9.PubMedCrossRefGoogle Scholar
  121. Kelly PA, Djiane J, Postel-Vinay MC, Edery M. The prolactin/growth hormone receptor family. Endocr Rev. 1991;12:235–51.PubMedCrossRefGoogle Scholar
  122. Keye WR, Yuen BH, Knopf RF, Jaffe RB. Amenorrhea, hyperprolactinemia and pituitary enlargement secondary to primary hypothyroidism. Successful treatment with thyroid replacement. Obstet Gynecol. 1976;48:697–702.PubMedGoogle Scholar
  123. Kharlip J, Salvatori R, Yenokyan G, Wand GS. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab. 2009;94:2428–36.PubMedPubMedCentralCrossRefGoogle Scholar
  124. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinaemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28:55–68.PubMedCrossRefGoogle Scholar
  125. Kleinberg DL, Noel GL, Frantz AG. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med Mar. 1977;296:589–600.CrossRefGoogle Scholar
  126. Klibanski A, Greenspan SL. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med. 1986;315:542–6.PubMedCrossRefGoogle Scholar
  127. Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, McArthur JW. Decreased bone density in hyperprolactinemic women. N Engl J Med. 1980;303:1511–4.PubMedCrossRefGoogle Scholar
  128. Kokay IC, Petersen SL, Grattan DR. Identification of prolactin-sensitive GABA and kisspeptin neurons in regions of the rat hypothalamus involved in the control of fertility. Endocrinology. 2011;152:526–35.PubMedCrossRefGoogle Scholar
  129. Kong DS, Lee JI, Lim DH, Kim KW, Shin HJ, Nam DH, Park K, Kim JH. The efficacy of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas: long-term results of 125 consecutive patients treated in a single institution. Cancer. 2007;110:854–60.PubMedCrossRefGoogle Scholar
  130. Kooy A, de Greef WJ, Vreeburg JT, Hackeng WH, Ooms MP, Lamberts SW, Weber RF. Evidence for the involvement of corticotropin-releasing factor in the inhibition of gonadotropin release induced by hyperprolactinemia. Neuroendocrinology. 1990;51:261–6.PubMedCrossRefGoogle Scholar
  131. Kovacs K, Stefaneanu L, Horvath E, Buchfelder M, Fahlbusch R, Becker W. Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. Case report. J Neurosurg. 1995;82:886–90.PubMedCrossRefGoogle Scholar
  132. Krasnow JS, Hickey GJ, Richards JS. Regulation of aromatase mRNA and estradiol biosynthesis in rat ovarian granulosa and luteal cells by prolactin. Mol Endocrinol. 1990;4:13–22.PubMedCrossRefGoogle Scholar
  133. Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, Buchfelder M. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol. 2008;158:11–8.PubMedCrossRefGoogle Scholar
  134. Kukstas LA, Domec C, Bascles L, Bonnet J, Verrier D, Israel JM, Vincent JD. Different expression of the two dopaminergic D2 receptors, D2415 and D2444, in two types of lactotroph each characterized by their response to dopamine, and modification of expression by sex steroids. Endocrinology. 1991;129:1101–3.PubMedCrossRefGoogle Scholar
  135. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, Pierard L, Beckers A. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol. 2008;159:1–5.PubMedCrossRefGoogle Scholar
  136. Lania AG, Ferrero S, Pivonello R, Mantovani G, Peverelli E, Di Sarno A, Beck-Peccoz P, Spada A, Colao A. Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J Clin Endocrinol Metab. 2010;95:13–7.PubMedCrossRefGoogle Scholar
  137. Leanos-Miranda A, Cardenas-Mondragon G. Serum free prolactin concentrations in patients with systemic lupus erythematosus are associated with lupus activity. Rheumatology. 2006;45:97–101.PubMedCrossRefGoogle Scholar
  138. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.PubMedCrossRefGoogle Scholar
  139. Lim VS, Kathpalia SC, Frohman LA. Hyperprolactinemia and impaired pituitary response to suppression and stimulation in chronic renal failure: reversal after transplantation. J Clin Endocrinol Metab. 1979;48:101–7.PubMedCrossRefGoogle Scholar
  140. Lin Y, Hyde JF, Vore M. Prolactin regulates maternal bile secretory function post partum. J Pharmacol Exp Ther. 1992;261:560–6.Google Scholar
  141. Ling C, Svensson L, Odén B, Weijdegård B, Edén B, Edén S, Billig H. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab. 2003;88:1804–8.PubMedCrossRefGoogle Scholar
  142. Lotti F, Corona G, Maseroli E, Rossi M, Silverii A, Degl’innocenti S, Rastrelli G, Forti G, Maggi M. Clinical implications of measuring prolactin levels in males of infertile couples. Andrology. 2013;1:764–71.PubMedCrossRefGoogle Scholar
  143. Lu ML, Shen WW, Chen CH. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32:1978–81.CrossRefGoogle Scholar
  144. Luciano AA, Sherman BM, Chapler FK, Hauser KS, Wallace RB. Hyperprolactinemia and contraception: a prospective study. Obstet Gynecol. 1985;65:506–10.PubMedGoogle Scholar
  145. Machida T, Taga M, Minaguchi H. Effect of prolactin (PRL) on lipoprotein lipase (LPL) activity in the rat fetal liver. Asia Oceania J Obstet Gynaecol. 1990;16:261–5.PubMedCrossRefGoogle Scholar
  146. Malaguarnera L, Pilastro MR, Quan S, Ghattas MH, Yang L, Mezentsev AV, Kushida T, Abraham NG, Kappas A. Significance of heme oxygenase in prolactin-mediated cell proliferation and angiogenesis in human endothelial cells. Int J Mol Med. 2002;10:433–40.PubMedGoogle Scholar
  147. Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin N Am. 2008;37:67–99.CrossRefGoogle Scholar
  148. Manjer J, Johansson R, Berglund G, Janzon L, Kaaks R, Agren A, Lenner P. Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes Control. 2003;14:599–607.PubMedCrossRefGoogle Scholar
  149. Matsuzaki T, Azuma K, Irahara M, Yasui T, Aono T. Mechanism of anovulation in hyperprolactinemic amenorrhea determined by pulsatile gonadotropin-releasing hormone injection combined with human chorionic gonadotropin. Fertil Steril. 1994;62:1143–9.PubMedCrossRefGoogle Scholar
  150. Mazziotti G, Porcelli T, Mormando M, De Menis E, Bianchi A, Mejia C, Mancini T, De Marinis L, Giustina A. Vertebral fractures in males with prolactinoma. Endocrine. 2011;39:288–93.PubMedCrossRefGoogle Scholar
  151. McNatty KP. Relationship between plasma prolactin and the endocrine microenvironment of the developing human antral follicle. Fertil Steril. 1979;32:433–8.PubMedCrossRefGoogle Scholar
  152. Melmed S, Kleinberg D. Anterior pituitary. In: Larsen P, Kronenberg H, Melmed S, Polonsky K, editors. Williams textbook of endocrinology. 10th ed. Philadelphia: Saunders; 2003. p. 177–279.Google Scholar
  153. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA, Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273–88.PubMedCrossRefGoogle Scholar
  154. Meltzer HY, Fang VS. Serum prolactin levels in schizophrenia-effect of antipsychotic drugs: a preliminary report. In: Sachar EJ, editor. Hormones, behavior, and psychopathology. New York: Raven Press; 1976.Google Scholar
  155. Mendelson JH, Mello NK, Teoh SK, Ellingboe J, Cochin J. Cocaine effects on pulsatile secretion of anterior pituitary, gonadal, and adrenal hormones. J Clin Endocrinol Metab. 1989;69:1256–60.PubMedCrossRefGoogle Scholar
  156. Mingrone G, Manco M, Iaconelli A, Gniuli D, Bracaglia R, Leccesi L, Calvani M, Nolfe G, Basu S, Berria R. Prolactin and insulin ultradian secretion and adipose tissue lipoprotein lipase expression in severely obese women after bariatric surgery. Obesity (Silver Spring). 2008;16:1831–7.CrossRefGoogle Scholar
  157. Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. 2002;87:5001–7.PubMedCrossRefGoogle Scholar
  158. Moffat SD, Zonderman AB, Metter EJ, Kawas C, Blackman MR, Harman SM, Resnick SM. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004;27(62):188–93.CrossRefGoogle Scholar
  159. Molinari C, Grossini E, Mary DA, Uberti F, Ghigo E, Ribichini F, Surico N, Vacca G. Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms. Endocrinology. 2007;148:4080–90.PubMedCrossRefGoogle Scholar
  160. Molitch ME. Pathologic hyperprolactinemia. Endocrinol Metab Clin N Am. 1992;21:877–901.Google Scholar
  161. Molitch ME. Prolactinoma. In: Melmed S, editor. Pituitary. Cambridge: Blackwell Science; 1995. p. 433–77.Google Scholar
  162. Molitch ME. Dopamine resistance of prolactinomas. Pituitary. 2003;6:19–27.PubMedCrossRefGoogle Scholar
  163. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005a;80:1050–7.PubMedCrossRefGoogle Scholar
  164. Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary. 2005b;8:43–52.PubMedCrossRefGoogle Scholar
  165. Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172:R205–13.PubMedCrossRefGoogle Scholar
  166. Molitch ME, Reichlin S. Hyperprolactinemic disorders. Dis Mon. 1982;28:1–58.PubMedCrossRefGoogle Scholar
  167. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. 1985;60:698–705.PubMedCrossRefGoogle Scholar
  168. Montejo AL. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol. 2008;18:101–30.CrossRefGoogle Scholar
  169. Montejo AL, Rico-Villademoros F, Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: a 3-month prospective, observational study. J Clin Psychopharmacol. 2008;28:568–70.PubMedCrossRefGoogle Scholar
  170. Montes de Oca P, Macotela Y, Nava G, López-Barrera F, de la Escalera GM, Clapp C. Prolactin stimulates integrin-mediated adhesion of circulating mononuclear cells to endothelial cells. Lab Investig. 2005;85:633–42.PubMedCrossRefGoogle Scholar
  171. Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol. 1996;135:413–20.PubMedCrossRefGoogle Scholar
  172. Morley JE, Dawson M, Hodgkinson H, Kalk WJ. Galactorrhea and hyperprolactinemia associated with chest wall injury. J Clin Endocrinol Metab. 1977;45:931–5.PubMedCrossRefGoogle Scholar
  173. Nevalainen MT, Valve EM, Ahonen T, Yagi A, Paranko J, Härkönen PL. Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture. FASEB J. 1997a;11:1297–307.PubMedCrossRefGoogle Scholar
  174. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, Harkonen PL. Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest. 1997b;99:618–27.PubMedPubMedCentralCrossRefGoogle Scholar
  175. Newey PJ, Gorvin CM, Cleland SJ, Willberg CB, Bridge M, Azharuddin M, Drummond RS, van der Merwe PA, Klenerman P, Bountra C, Thakker RV. Mutant prolactin receptor and familial hyperprolactinemia. N Engl J Med. 2013;369:2012–20.PubMedPubMedCentralCrossRefGoogle Scholar
  176. Nicol M, Willis C, Yiangou C, Sinnett D, Shousha S. Relationship between serum prolactin levels and histology of benign and malignant breast lesions: a detailed study of 153 consecutive cases. Breast J. 2002;8:281–5.PubMedCrossRefGoogle Scholar
  177. Nicoll C. Ontogeny and evolution of prolactins' function. Fed Proc. 1980;39:2563–6.PubMedGoogle Scholar
  178. Nilsson L, Binart N, Bohlooly-Y M, Bramnert M, Egecioglu E, Kindblom J, Kelly PA, Kopchick JJ, Ormandy CJ, Ling C, Billig H (2005) Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun 331: 1120-1126Google Scholar
  179. Nomikos P, Buchfelder M, Fahlbusch R. Current management of prolactinomas. J Neuro-Oncol. 2001;54:139–50.CrossRefGoogle Scholar
  180. Oh MC, Aghi MK. Dopamine agonist-resistant prolactinomas. J Neurosurg. 2011;114:1369–79.PubMedCrossRefGoogle Scholar
  181. Oliveira MC, Pizarro CB, Golbert L, Micheletto C. Hyperprolactinemia and psychological disturbance. Arq Neuropsiquiatr. 2000;58:671–6.PubMedCrossRefGoogle Scholar
  182. Orbach H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev. 2007;6:537–42.PubMedCrossRefGoogle Scholar
  183. Pan L, Zhang N, Wang EM, Wang BJ, Dai JZ, Cai PW. Gamma knife radiosurgery as a primary treatment for prolactinomas. J Neurosurg. 2000;93:10–3.PubMedGoogle Scholar
  184. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab. 1989;69:500–9.PubMedCrossRefGoogle Scholar
  185. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology. 1992;17:485–95.PubMedCrossRefGoogle Scholar
  186. Pinsky M, Hellstrom W. Hypogonadism, ADAM, and hormone replacement. Ther Adv Urol. 2010;2:99–104.PubMedPubMedCentralCrossRefGoogle Scholar
  187. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab. 2000;85:3053–7.PubMedGoogle Scholar
  188. Pippard C, Baylis PH. Prolactin stimulates Na+-K+-ATPase activity located in the outer renal medulla of the rat. J Endocrinol. 1986;108:95–9.PubMedCrossRefGoogle Scholar
  189. Pollock A, McLaren EH. Serum prolactin concentration in patients taking neuroleptic drugs. Clin Endocrinol. 1998;49:513–6.CrossRefGoogle Scholar
  190. Postel-Vinay MC, Belair L, Kayser C, Kelly PA, Djiane J. Identification of prolactin and growth hormone binding proteins in milk. Proc Natl Acad Sci U S A. 1991;188:6687–90.CrossRefGoogle Scholar
  191. Poyraz BC, Aksoy C, Balcioglu I. Increased incidence of autoimmune thyroiditis in patients with antipsychotic-induced hyperprolactinemia. Eur Neuropsychopharmacol. 2008;18:667–72.PubMedCrossRefGoogle Scholar
  192. Prabhakar VK, Davis JR. Hyperprolactinemia. Best Pract Res Clin Obstet Gynaecol. 2008;22:341–53.PubMedCrossRefGoogle Scholar
  193. Pujianto DA, Curry BJ, Aitken RJ. Prolactin exerts a prosurvival effect on human spermatozoa via mechanisms that involve the stimulation of Akt phosphorylation and suppression of caspase activation and capacitation. Endocrinology. 2010;151:1269–79.PubMedCrossRefGoogle Scholar
  194. Ramasharma K, Li CH. Human pituitary and placental hormones control human insulin-like growth factor II secretion in human granulosa cells. Proc Natl Acad Sci U S A. 1987;84:2643–7.PubMedPubMedCentralCrossRefGoogle Scholar
  195. Ravault JP, Courot M, Garnier D, Pelletier J, Terqui M. Effect of 2-bromo-α-ergocryptine (CB154) on plasma prolactin, LH and testosterone levels, accessory reproductive glands and spermatogenesis in lambs during puberty. Biol Reprod. 1977;17:192–7.PubMedCrossRefGoogle Scholar
  196. Reavley A, Fisher AD, Owen D, Creed FH, Davis JR. Psychological distress in patients with hyperprolactinaemia. Clin Endocrinol. 1997;47:343–8.CrossRefGoogle Scholar
  197. Ress C, Maeser PA, Tschoner A, Loacker L, Salzmann K, Staudacher G, Melmer A, Zoller H, Vogel W, Griesmacher A, Tilg H, Graziadei I, Kaser S. Serum prolactin in advanced chronic liver disease. Horm Metab Res. 2014;46:800–3.PubMedCrossRefGoogle Scholar
  198. Reuwer AQ, Twickler MT, Hutten BA, Molema FW, Wareham NJ, Dallinga-Thie GM, Bogorad RL, Goffin V, Smink-Bol M, Kastelein JJ, Boekholdt SM, Khaw KT. Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. Circ Cardiovasc Genet. 2009;2:389–95.PubMedCrossRefGoogle Scholar
  199. Reuwer AQ, van Eijk M, Houttuijn-Bloemendaal FM, van der Loos CM, Claessen N, Teeling P, Kastelein JJ, Hamann J, Goffin V, von der Thüsen JH, Twickler MT, Aten J. The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogenesis? J Endocrinol. 2011;208:107–17.PubMedCrossRefGoogle Scholar
  200. Richardsson BP. Evidence for a physiological role of prolactin in osmoregulation in the rat after its inhibition by 2-bromo-α-ergokryptine. Br J Pharmacol. 1973;47:623–4.Google Scholar
  201. Rickenlund A, Thoren M, Carlstrom K, von Schoultz B, Hirschberg AL. Diurnal profiles of testosterone and pituitary hormones suggest different mechanisms for menstrual disturbances in endurance athletes. J Clin Endocrinol Metab. 2004;89:702–7.PubMedCrossRefGoogle Scholar
  202. Rohmer V, Freneau E, Morange I, Simonetta C. Efficacy of quinagolide in resistance to dopamine agonists: results of a multi-center study. Club de l’Hypophyse. Ann Endocrinol (Paris). 2000;61:411–7.Google Scholar
  203. Rubin RT, Poland RE, Tower BB. Prolactin-related testosterone secretion in normal adult men. J Clin Endocrinol Metab. 1976;42:112–6.PubMedCrossRefGoogle Scholar
  204. Saitis M, Papazisis G, Katsigiannopoulos K, Kouvelas D. Aripiprazole resolves amisulpride and ziprasidone-induced hyperprolactinemia. Psychiatry Clin Neurosci. 2008;62:624.PubMedCrossRefGoogle Scholar
  205. Samson SL, Hamrahian AH, Ezzat S, AACE Neuroendocrine and Pituitary Scientific Committee, American College of Endocrinology (ACE). American association of clinical endocrinologists, American college of endocrinology disease state clinical review: clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia. Endocr Pract. 2015;21:1427–35.PubMedCrossRefGoogle Scholar
  206. Sauder SE, Frager M, Case GD, Kelch RP, Marshall JC. Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea: responses to bromocriptine. J Clin Endocrinol Metab. 1984;59:941–8.PubMedCrossRefGoogle Scholar
  207. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356:29–38.PubMedCrossRefGoogle Scholar
  208. Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med. 2003;349:2035–41.PubMedCrossRefGoogle Scholar
  209. Schlechte JA, Sherman BM, Chapler FK, VanGilder J. Long-term follow-up of women with surgically treated prolactin-secreting pituitary tumours. J Clin Endocrinol Metab. 1986;62:1296–301.PubMedCrossRefGoogle Scholar
  210. Schlechte J, El-Khoury G, Kathol M, Walkner L. Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab. 1987;64:1021–6.PubMedCrossRefGoogle Scholar
  211. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab. 1989;68:412–8.PubMedCrossRefGoogle Scholar
  212. Seppala M, Ranta T, Hirvonen E. Hyperprolactinaemia and luteal insufficiency. Lancet. 1976;1:229–30.PubMedCrossRefGoogle Scholar
  213. Seriwatanachai D, Krishnamra N, van Leeuwen JP. Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. J Cell Biochem. 2009;107:677–85.PubMedCrossRefGoogle Scholar
  214. Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol. 2006;64:366–70.Google Scholar
  215. Shelly S, Boaz M, Orbach H. Prolactin and autoimmunity. Autoimmun Rev. 2012;11:A465–70.PubMedCrossRefGoogle Scholar
  216. Shibli-Rahhal A, Schlechte J. The effects of hyperprolactinemia on bone and fat. Pituitary. 2009;12:96–104.PubMedCrossRefGoogle Scholar
  217. Sievertsen GD, Lim VS, Nakawatase C, Frohman LA. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J Clin Endocrinol Metab. 1980;50:846–52.PubMedCrossRefGoogle Scholar
  218. Skrabanek P, McDonald D, de Valera E, Lanigan O, Powell D. Plasma prolactin in amenorrhoea, infertility, and other disorders: a retrospective study of 608 patients. Ir J Med Sci. 1980;149:236–45.PubMedCrossRefGoogle Scholar
  219. Sluijmer AV, Lappöhn RE. Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil Steril. 1992;58:72–7.PubMedCrossRefGoogle Scholar
  220. Smith S. Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine? J Reprod Med. 1992;37:737–40.PubMedGoogle Scholar
  221. Smith S. The impact of hyperprolactinaemia on sexual function in patients with psychosis. J Psychopharmacol. 2008;22:63–9.PubMedCrossRefGoogle Scholar
  222. Smith TP, Suliman AM, Fahie-Wilson MN, McKenna TJ. Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J Clin Endocrinol Metab. 2002a;87:5410–5.PubMedCrossRefGoogle Scholar
  223. Smith S, Wheeler MJ, Murray R, O’Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol. 2002b;22:109–14.PubMedCrossRefGoogle Scholar
  224. Sobrinho LG. Familial prolactinoma. Clin Endocrinol. 1995;43:511.CrossRefGoogle Scholar
  225. Sobrinho LG. Emotional aspects of hyperprolactinemia. Psychother Psychosom. 1998;67:133–9.PubMedCrossRefGoogle Scholar
  226. Sonigo C, Bouilly J, Carré N, Tolle V, Caraty A, Tello J, Simony-Conesa FJ, Millar R, Young J, Binart N. Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J Clin Invest. 2012;122:3791–5.PubMedPubMedCentralCrossRefGoogle Scholar
  227. Sorenson RL, Brelie TC, Hegie OD, Marshall S, Anaya P, Sheridam JD. Prolactin (in vitro) decreases the glucose stimulation threshold, enhances insulin secretion, and increases dye coupling among islet b cells. Endocrinology. 1987;121:1447–53.PubMedCrossRefGoogle Scholar
  228. Spitzer M, Sajjad R, Benjamin F. Pattern of development of hyperprolactinemia after initiation of haloperidol therapy. Obstet Gynecol. 1998;91:693–5.PubMedGoogle Scholar
  229. St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol. 1996;44:305–9.CrossRefGoogle Scholar
  230. Svestka J, Synek O, Tomanová J, Rodáková I, Cejpková A. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Neuro Endocrinol Lett. 2007;28:881–8.PubMedGoogle Scholar
  231. Szosland K, Stasiak M, Lewiński A. Hyperprolactinemia diagnostics-dilemmas over optimal selection of prolactinemia time points. Ann Agric Environ Med. 2015;22:332–7.PubMedCrossRefGoogle Scholar
  232. Takase M, Tsutsui K, Kawashima S. Effects of prolactin and bromocryptine on the regulation of testicular luteinizing hormone receptors in mice. J Exp Zool. 1990;256:200–9.PubMedCrossRefGoogle Scholar
  233. Takeyama M, Nagareda T, Takatsuka D, Namiki M, Koizumi K, Aono T, Matsumoto K. Stimulatory effect of prolactin on luteinizing hormone-induced testicular 5 alpha-reductase activity in hypophysectomized adult rats. Endocrinology. 1986;118:2268–75.PubMedCrossRefGoogle Scholar
  234. Tolis G, Hickey J, Guyda H. Effects of morphine on serum growth hormone, cortisol, prolactin and thyroid stimulating hormone in man. J Clin Endocrinol Metab. 1975;41:797–800.PubMedCrossRefGoogle Scholar
  235. Tollin SR. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Investig. 2000;23:765–70.CrossRefGoogle Scholar
  236. Unnikrishnan AG, Rajaratnam S, Seshadri MS, Kanagasapabathy AS, Stephen DC. The “hook effect” on serum prolactin estimation in a patient with macroprolactinoma. Neurol India. 2001;49:78–80.PubMedGoogle Scholar
  237. Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, Aris-Jilwan N, Houde G, Serri O. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary. 2009;12:153–7.PubMedCrossRefGoogle Scholar
  238. Vera-Lastra O, Jara LJ, Espinoza LR. Prolactin and autoimmunity. Autoimmun Rev. 2002;1:360–4.PubMedCrossRefGoogle Scholar
  239. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84:2518–22.PubMedCrossRefGoogle Scholar
  240. Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry. 2004;65:57–61.PubMedCrossRefGoogle Scholar
  241. Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Chanson P, Vilar L, Borson-Chazot F, Naves LA, Brue T, Gatta B, Delemer B, Ciccarelli E, Beck-Peccoz P, Caron P, Daly AF, Beckers A. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol. 2012;167:651–62.PubMedCrossRefGoogle Scholar
  242. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol. 2008;159:R11–4.PubMedCrossRefGoogle Scholar
  243. Wallaschofski H, Donné M, Eigenthaler M, Hentschel B, Faber R, Stepan H, Koksch M, Lohmann T. PRL as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab. 2001;86:5912–9.PubMedCrossRefGoogle Scholar
  244. Walsh JP, Pullan PT. Hyperprolactinaemia in males: a heterogeneous disorder. Aust NZ J Med. 1997;27:385–90.CrossRefGoogle Scholar
  245. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhoea. Cabergoline Comparative Study Group. N Engl J Med. 1994;331:904–9.PubMedCrossRefGoogle Scholar
  246. Winters SJ, Troen P. Altered pulsatile secretion of luteinizing hormone in hypogonadal men with hyperprolactinaemia. Clin Endocrinol. 1984;21:257–63.CrossRefGoogle Scholar
  247. Wong A, Eloy JA, Couldwell WT, Liu J. Update on prolactinomas. Part 2: treatment and management strategies. J Clin Neurosci. 2015;22:1568–74.PubMedCrossRefGoogle Scholar
  248. Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gözü H, Sezgin O, Haklar G, Akalin S. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol. 2003;149:187–93.PubMedCrossRefGoogle Scholar
  249. Yazigi RA, Quintero CH, Salameh WA. Prolactin disorders. Fertil Steril. 1997;67:215–25.PubMedCrossRefGoogle Scholar
  250. Yener S, Comlekci A, Arda N, Men S, Yesil S. Misdiagnosis due to the hook effect in prolactin assay. Med Princ Pract. 2008;17:429–31.PubMedCrossRefGoogle Scholar
  251. Yu-Lee LY. Prolactin modulation of immune and inflammatory responses. Recent Prog Horm Res. 2002;57:435–55.PubMedCrossRefGoogle Scholar
  252. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356:39–46.PubMedCrossRefGoogle Scholar
  253. Zellweger R, Zhu XH, Wichmann MW, Ayala A, DeMaso CM, Chaudry IH. Prolactin administration following hemorrhagic shock improves macrophage cytokine release capacity and decreases mortality from subsequent sepsis. J Immunol. 1996;157:5748–54.PubMedGoogle Scholar
  254. Zis AP, Haskett RF, Albala AA, Carroll BJ. Morphine inhibits cortisol and stimulates prolactin secretion in man. Psychoneuroendocrinology. 1984;9:423–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Medical Science, Division of Endocrinology, Diabetes and MetabolismTurinItaly

Personalised recommendations